The Motley Fool
23 Feb 2026, 21:44 UTC · 28w ago
Verdict
Headline leans bullish. We score IBRX +0.80 across five claims.
Score confirms the headline.
IBRX score
+0.80
More positive than 88% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
5 claims · scored −1 bearish … +1 bullish
ImmunityBio's primary biologic product, Anktiva, experienced 700% revenue growth in 2025.
So whatMassive top-line growth for a lead product is a primary driver of valuation in biotech.
More positive than 98% of claims this week
Anktiva received approval in Saudi Arabia for the treatment of certain types of lung cancer.
Continue reading
5 related stories
Search tags
More positive than 91% of claims this week
ImmunityBio has secured approvals for Anktiva across 33 countries, including the U.S., E.U., and U.K.
More positive than 85% of claims this week
The company is increasing clinical trial enrollment for glioblastoma, sepsis, non-Hodgkin lymphoma, and lymphopenia.
More positive than 77% of claims this week
ImmunityBio's stock has already quintupled in value during 2026.
So whatRapid price appreciation may lead to overvaluation and increased risk of a correction.
More negative than 72% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Significant revenue growth for Anktiva, narrowing losses, and expanding international approvals.
More positive than 67% of ticker scores this week
Mentioned as an industry peer showing strength with a notable price increase.
More positive than 54% of ticker scores this week
Mentioned as an industry peer showing strength with a slight price increase.
More positive than 13% of relationship scores this week
[mutual] Identified as industry peers within the biotechnology sector and drug development.
More positive than 13% of relationship scores this week
[mutual] Identified as industry peers within the biotechnology sector and drug development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
More positive than 13% of relationship scores this week
[mutual] Identified as industry peers within the biotechnology sector and drug development.
Price reaction
Expected +0.80Actual −19.5%
Price is moving against the score
139 sessions since publication. $7.91 vs $9.83 close before publication (Feb 23). Not market-adjusted.
IBRX chart →
